£25.0M
The Oxford-based medical technology company secured backing from Lauxera Capital Partners to expand its US footprint and advance research pipelines.
"Lauxera is proud and honoured to back the OrganOx team and its global commercial scale-up. This is the ninth investment made by Lauxera Growth I, a growth buy-out fund dedicated to investing in commercial-stage European and North American HealthTech businesses."
